CROMOLYN SUMMARY
CROMOLYN SODIUM
OPHTHALMIC SOLUTION, USP 4%
Cromolyn Sodium Ophthalmic Solution, USP 4% is a clear, colorless, sterile solution intended for topical ophthalmic use.
Cromolyn Sodium Ophthalmic Solution, USP 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
|
NEWS HIGHLIGHTSMedia Articles Related to Cromolyn (Cromolyn Ophthalmic)
What Is Dry Eye Syndrome? What Causes Dry Eye Syndrome?
Source: Eye Health / Blindness News From Medical News Today [2009.11.12]
Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), keratitis sicca, sicca syndrome, xerophthalmia, or simply dry eyes, is an eye disease in which tear film evaporation is high or tear production is low. Dry eye syndrome is commonly found in humans and some animals. The patient's eyes dry out and become inflamed.
Published Studies Related to Cromolyn (Cromolyn Ophthalmic)
Gamma scintigraphy for testing bioequivalence: a case study on two cromolyn sodium nasal spray preparations. [2008.06.05]
The present work was carried out to study the deposition patterns and clearance of technetium-99m (99mTc) DTPA labeled cromolyn sodium (CS) solutions when administered from two different CS nasal products using gamma scintigraphy. Five healthy volunteers received a single dose with complete crossover design involving treatment A (test formulation) and treatment B (reference formulation).
Promising ternary dry powder inhaler formulations of cromolyn sodium: formulation and in vitro-in vivo evaluation. [2007.06]
Glucose monohydrate and sorbitol were evaluated as alternative carriers to a-lactose monohydrate in dry powder inhalations. Cromolyn sodium (CS) - carrier binary formulae were prepared and tested in vitro by aerosolization via a twin stage impinger using three types of inhaler devices; Spinhaler, Aerolizer and Handihaler...
Cromolyn sodium: a potential therapy for uremic pruritus? [2006.04]
Uremic pruritus occurs in up to 50% of patients undergoing chronic hemodialysis. The pathogenesis of this disabling condition is unknown but likely involves multiple pathways involving the peripheral and central nervous system as well as local chemical and inflammatory mediators.Cromolyn sodium may offer an alternative therapy for patients with refractory uremic pruritus, and should be subjected to a randomized placebo-controlled trial.
Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. [2008.12]
BACKGROUND: Medications are frequently combined in the nebulizer cup, so it is important to determine their chemical and physical compatibility. OBJECTIVE: To determine the chemical and physical compatibility of levalbuterol with ipratropium bromide, cromolyn sodium, acetylcysteine sodium, and budesonide... CONCLUSIONS: The 2-drug admixtures we studied were compatible for at least 30 min at room temperature.
Influence of Ketotifen, Cromolyn Sodium, and Compound 48/80 on the survival rates after intestinal ischemia reperfusion injury in rats. [2008.09.22]
BACKGROUND: Mast cells were associated with intestinal ischemia-reperfusion injury, the study was to observe the influence of Ketotifen, Cromolyn Sdium(CS), and Compound 48/80(CP) on the survival rates on the third day after intestinal ischemia-reperfusion injury in rats... CONCLUSION: Mast cell inhibition after ischemia prior to reperfusion and following reperfusion may decrease the multi-organ injury induced by intestine ischemia reperfusion, and increase the survival rates.
Clinical Trials Related to Cromolyn (Cromolyn Ophthalmic)
Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus [Recruiting]
Pruritus is a major disorder among the skin derangements in advanced renal failure. Recent
information suggests that interactions between dermal mast cells and distal ends of
nonmyelinated C fibers may be important in the precipitation and regulation of the sensory
stimuli. Patients having uremic pruritus have been noted to have increased levels of plasma
histamine and tryptase as well as increased numbers of dermal mast cells. Cromolyn sodium is a
mast cell stabilizing agent that inhibits degranulation of mast cells and the release of
histamine, tryptase, and leukotrienes. It is hypothesized that oral cromolyn sodium may
attenuate uremic pruritus by decreasing serum tryptase level.
To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol [Recruiting]
This is a multicentre, randomised, double-blind, placebo-controlled, 4-way cross-over study.
At each study visit a standardised treadmill test will be performed to provoke EIA. Before
and after the challenge test pulmonary function variables (e. g. forced expiratory volume in
one second (FEV1)) will be measured in order to assess the protective effect of the study
medication.
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab [Recruiting]
Eosinophilic esophagitis (EE) is an increasingly recognized condition characterized by
dysphagia, food impaction or other obstructive esophageal symptoms in children and young
adults.
The pathophysiology of EE appears to be an allergy/atopy mediated disease. A personal and
family history of allergic diseases (food allergies, atopic dermatitis, asthma, allergic
rhinitis or conjunctivitis) has been noted in 62-85% of patients with EE. The rising
incidence of EE may be related to the worldwide allergy and asthma epidemic.
Current treatment of EE is directed at decreasing esophageal allergic inflammation. Oral and
topical corticosteroids, cromolyn sodium, montelukast and elemental/elimination diets have
all been shown to be effective. However, none of these treatments are directed at the
specific pathophysiologic mechanism of EE and some have significant side effects.
The shared pathogenetic mechanisms of EE and asthma suggest that therapeutic strategies
directed at asthma may also be effective for EE. Specifically those targeted at the allergic
immune mechanisms involved with asthma may be effective. Omalizumab is a recently developed
anti-IgE antibody that has been shown to decrease the use of inhaled and oral
corticosteroids, reduce the frequency of asthma exacerbations, and improve asthma related
symptoms in patients with allergic asthma. The objective of the study is to determine the
efficacy of omalizumab in the treatment of eosinophilic esophagitis
|
